TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21926181

Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg) in short-term study
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg/day) in long-term study
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anthocyanins with NO-cGMP inhibitors
Number of subjects: 150
Study: 18242276

Group type: EXPERIMENTAL
Intervention: Preoperative statin use
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Higher intensity statin dosing (>= 40 mg atorvastatin)
Number of subjects: 555

Group type: COMPARATOR
Intervention: No statin use (Control)
Number of subjects: 555
Study: 16595499

Group type: EXPERIMENTAL
Intervention: rhTSH
Number of subjects: 63

Group type: COMPARATOR
Intervention: THW
Number of subjects: 63
Study: 12911777

Group type: EXPERIMENTAL
Intervention: Oral challenges with egg
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with peanut
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with milk
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with sesame
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with peanut oil
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with soy oil
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with sunflower oil
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Oral challenges with sesame oil
Number of subjects: 399
Study: 11139003

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention for 10 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 62
Study: 9086865

Group type: EXPERIMENTAL
Intervention: Exposure combined with hypnosis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 64
Study: 8385793

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2868771

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (25 micrograms/h)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (isotonic saline 125 ml/h)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms b.d. subcutaneously)
Number of subjects: 5
Study: 29911906

Group type: EXPERIMENTAL
Intervention: Miniscrew‐anchored inverted Forsus FRD
Number of subjects: 16
Study: 27855109

Group type: EXPERIMENTAL
Intervention: Immediate adaptations (no wait)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual adaptations (∼3-month wait)
Number of subjects: 50
Study: 23959961

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (6-week full-body program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22872218

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily subcutaneous injection)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bisphosphonate (17.5 mg weekly oral risedronate)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 20689926

Group type: EXPERIMENTAL
Intervention: Adjusted analysis including all patients
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Adjusted analysis excluding patients with missing deferred consent
Number of subjects: 348
Study: 17917707

Group type: COMPARATOR
Intervention: sCD40L levels measured in citrated plasma
Number of subjects: 2403

Group type: COMPARATOR
Intervention: sCD40L levels measured in plasma
Number of subjects: 2403

Group type: COMPARATOR
Intervention: sCD40L levels measured in serum
Number of subjects: 2403

Group type: COMPARATOR
Intervention: sCD40L levels measured in serum vs plasma
Number of subjects: 2403
Study: 16873787

Group type: EXPERIMENTAL
Intervention: sulfonylurea plus 1,000 microg Cr as CrPic
Number of subjects: 37

Group type: COMPARATOR
Intervention: sulfonylurea plus placebo
Number of subjects: 37
Study: 12791113

Group type: EXPERIMENTAL
Intervention: 0.7 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1.0 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.7 ml.kg-1, 1.0 ml.kg-1, 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54
Study: 10739792

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 9
Study: 9376887

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 1398281

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg intramuscularly twice a day starting the day before surgery)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcium Heparin (5000 IU subcutaneously twice daily beginning 2 hours before surgery)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcium Heparin
Number of subjects: 81
Study: 3912189

Group type: EXPERIMENTAL
Intervention: Vindeburnol 30, 60 or 90 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31103981

Group type: EXPERIMENTAL
Intervention: Dermocosmetic emulgels loaded with Diospyros kaki fruit extract (DKFE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27888448

Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate 0.05% cream under occlusion with silicone dressing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intra-lesional triamcinolone
Number of subjects: 17
Study: 26409701

Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT) combined with routine medical therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine medical therapy alone
Number of subjects: 44
Study: 24010644

Group type: EXPERIMENTAL
Intervention: GS-0938 for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GS-0938 for 7 days followed by GS-0938 plus sofosbuvir for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sofosbuvir for 7 days followed by GS-0938 plus sofosbuvir for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GS-0938 plus sofosbuvir for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21213171

Group type: EXPERIMENTAL
Intervention: Seeing oneself on screen (exergame feature)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not seeing oneself on screen (exergame feature)
Number of subjects: 0
Study: 18005082

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in addition to transplanted bone
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 53
Study: 16799234

Group type: EXPERIMENTAL
Intervention: 30 mg edaravone intravenously just before reperfusion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 13679933

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30‐ to 45‐second delay in cord clamping)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 32
Study: 11125896

Group type: EXPERIMENTAL
Intervention: Health worker training and STD syndrome packets (containing recommended drugs, condoms, partner notification cards, and information leaflets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health worker training and STD syndrome packets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine syndromic management (control)
Number of subjects: 0
Study: 9136151

Group type: EXPERIMENTAL
Intervention: Moisturizing lotion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study: 1401622

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase, 150,000 U
Number of subjects: 93

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 93
Study: 3935203

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Tetracycline and Berberine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Berberine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 31908513

Group type: EXPERIMENTAL
Intervention: Wash+lotion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Water+lotion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 130
Study: 30152116

Group type: EXPERIMENTAL
Intervention: Dual induction therapy (rATG combined with either daclizumab or alemtuzumab) with planned early corticosteroid withdrawal
Number of subjects: 200
Study: 26266654

Group type: EXPERIMENTAL
Intervention: Silorane-based composite light-cured for 80 seconds at 800 mW/cm(2)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Silorane-based composite
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Both resin composites
Number of subjects: 432

Group type: COMPARATOR
Intervention: Methacrylate-based composite
Number of subjects: 432
Study: 23456215

Group type: EXPERIMENTAL
Intervention: Clown intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (routine procedure)
Number of subjects: 50
Study: 21909729

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Alendronate (70 mg/week)
Number of subjects: 83
Study: 20638351

Group type: EXPERIMENTAL
Intervention: Cognitive dissonance (CD)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Modified healthy weight (MHW)
Number of subjects: 106
Study: 17185636

Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no NPRIs)
Number of subjects: 32
Study: 15455791

Group type: EXPERIMENTAL
Intervention: Pre-dialysis clinic intervention
Number of subjects: 2200
Study: 11853894

Group type: EXPERIMENTAL
Intervention: Advice and relaxation tape
Number of subjects: 243

Group type: COMPARATOR
Intervention: Music tape of their choice
Number of subjects: 243
Study: 9667087

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) - individualized 30-minute therapy session with head, eye, and body exercises
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 143
Study: 9228466

Group type: EXPERIMENTAL
Intervention: 0.25 micrograms 1 alpha(OH)D3/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 0.50-0.75 micrograms 1 alpha(OH)D3/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study: 1742754

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg) administered via i.v. infusion starting 30 min before APO administration.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control group) administered via i.v. infusion starting 30 min before APO administration.
Number of subjects: 12
Study: 7023224

Group type: EXPERIMENTAL
Intervention: Bretylium tosylate
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 146
Study: 30542933

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham ultrasound (SHAM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 15
Study: 28902040

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg administered twice daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no rifaximin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 23622262

Group type: EXPERIMENTAL
Intervention: Cat saliva 9cH and Histaminum 9cH (combined), taken as two tablets twice daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21489086

Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 751

Group type: COMPARATOR
Intervention: Control (non-statin pretreatment)
Number of subjects: 751
Study: 19036752

Group type: EXPERIMENTAL
Intervention: Once-daily lamivudine, tenofovirDF and nevirapine (Group 2)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Zidovudine/lamivudine and nevirapine twice daily (Group 1)
Number of subjects: 250
Study: 17156512

Group type: COMPARATOR
Intervention: Standard pain treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electro acupuncture
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electro acupuncture at non-acupuncture points
Number of subjects: 15
Study: 15053120

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation head movement exercises (slow movement group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation head movement exercises (rapid movement group)
Number of subjects: 53
Study: 11291999

Group type: EXPERIMENTAL
Intervention: TYR-free amino acid drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAL amino acid drink
Number of subjects: 0
Study: 9223094

Group type: EXPERIMENTAL
Intervention: Phonemic fluency task
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Semantic fluency task
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 6
Study: 7801588

Group type: EXPERIMENTAL
Intervention: Local administration of metromidasole with dimethysulfoxide
Number of subjects: 669
Study: 3003259

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation therapy combined with chemotherapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 80
Study: 31233321

Group type: EXPERIMENTAL
Intervention: Experiences of stigma
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Internalized stigma
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Recovery orientation
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Perceived quality of life
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Social withdrawal
Number of subjects: 516
Study: 30156193

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - single dose immediately after surgery (0.3 W, 40 s, 4 J/cm2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group - sham therapy immediately after surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group - routine management (ice application)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (LLLT, placebo, control)
Number of subjects: 45
Study: 26458326

Group type: EXPERIMENTAL
Intervention: UCP1 -3826 A>G polymorphism (mutated allele G)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: UCP1 -3826 A>G polymorphism (mutated homozygotes GG)
Number of subjects: 150
Study: 24675245

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Olive oil and chewing gum
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study: 22983407

Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Stepwise excavation (SW)
Number of subjects: 299
Study: 20236791

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18349177

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16013662

Group type: EXPERIMENTAL
Intervention: 0.25 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.50 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline + propofol 2.5 mg kg(‐1)
Number of subjects: 60
Study: 12441717

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 10514958

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 8745672

Group type: EXPERIMENTAL
Intervention: Intravenous (iv) administration of 12 IU/m2/24 hours IL2, continuous infusion from day 5 to day 3 before surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous (sc) administration of 18 IU IL2, in 2 SC injections per day from day 4 to day 2 before surgery
Number of subjects: 18
Study: 1921784

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (10-30 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (1-3 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral levodopa
Number of subjects: 5
Study: 6405444

Group type: EXPERIMENTAL
Intervention: 8 mg IV naloxone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 31938829

Group type: EXPERIMENTAL
Intervention: Prophylactic pantoprazole
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3291
Study: 31261247

Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) group using the IBD Pocket Guide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 0
Study: 28976791

Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, and Infusional Fluorouracil (ECF)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Fluorouracil and Leucovorin (FU plus LV)
Number of subjects: 546
Study: 27555193

Group type: EXPERIMENTAL
Intervention: TAP block (15‐20 mL 0.5% ropivacaine, maximum 3 mg/kg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (20 to 30 mL 0.5% ropivacaine infiltrated preincision)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia fentanyl
Number of subjects: 71
Study: 25088940

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592
Study: 23130573

Group type: EXPERIMENTAL
Intervention: Enzyme supplemented diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (corn-soyabean without enzyme supplementation)
Number of subjects: 0
Study: 19852288

Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule (GPC) in group A
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule + Levodopa in group C
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo + Levodopa in group D
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule + Levodopa in group E
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo + Levodopa in group F
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Levodopa dosage in groups C and E
Number of subjects: 242
Study: 17501848

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: eletriptan 20 mg
Number of subjects: 613
Study: 15037889

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost instillation once daily in the morning
Number of subjects: 62

Group type: COMPARATOR
Intervention: 0.5% timolol instillation twice daily
Number of subjects: 62
Study: 11684631

Group type: EXPERIMENTAL
Intervention: Normal pregnancy (NP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension (PIH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normotensive nonpregnant (NN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postpartum (after delivery)
Number of subjects: 60
Study: 9687551

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg of oily solution of retinyl palmitate, 30 mg if aged <12 mo) every 6 mo
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) every 3 mo
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Deworming
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in boys
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in girls
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Deworming in boys and girls
Number of subjects: 358
Study: 7976148

Group type: EXPERIMENTAL
Intervention: Auscultation of the epigastrium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auscultation of the right axilla
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auscultation of the left axilla
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaesthetist's feeling when squeezing the bag
Number of subjects: 40
Study: 3141143

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/kg/d for those weighing less than 6 kg and 50 mg daily for those over 6 kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 60
Study: 31898518

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) with a restricted carbohydrate intake of 20-40 g/day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fasting Diet (FD) with a 7-day fast every 6 months and 14-hour daily intermittent fasting
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard Diet (SD) as recommended by the German Nutrition Society
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fasting Diet (FD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 111